Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)

Diana M. Gibb, A. Sarah Walker, Steve Kaye, Anita De Rossi, Mounir Ait-Khaled, Deenan Pillay, Maria Angeles Muñoz-Fernandez, Clive Loveday, Alexandra Compagnucci, David T. Dunn, Abdel G. Babiker

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences